Dolutegravir/Lamivudine Results in HIV Suppression in Small Treatment-Naive Cohort
A 2-drug antiretroviral therapy (ART) regimen of dolutegravir/lamivudine (DTG/3TC) resulted in sustained virologic suppression in patients with HIV infection, regardless of viral load at treatment initiation. These results were presented at IDWeek 20,22, which took place in Washington, DC, from October 19 through 23, 2022.
Researchers conducted a retrospective analysis at 24 US sites in order to evaluate the treatment outcomes for HIV-infected patients using DTG-based regimens. Eligible patients (N=469) included adults who received ART with either one tablet of DTG/3TC, or DTG/rilpivirine prior to September 2020. The minimum follow up period was 6 months. The researchers compared the clinical characteristics and treatment outcomes of treatment-naive patients who had at least 100,000 copies/mL HIV viral load when they received DTG/3TC.
318 patients were included in the analysis. 58 of these patients were naive to treatment, and had available data on their baseline viral loads. 9 of these patients had baseline viral load data between 100,000 and 250,000 copies/mL. 7 had viral loads greater then 250,000 copies/mL.
Subcohorts 1 to 2 had a median age of 34.0 years (range, 24-55), and 33.0 years (range, 25-53) respectively. 77.8% were men and 100% were women, 44.4% and 28.6%, respectively. The median CD4 count was 312 (IQR: 43.5-584) cells/mm and 114 (IQR: 29-481) at treatment initiation, respectively.3, respectively.
“
These real-world results reflect data from clinical studies, which show DTG/3TC is safe and effective in the real world.
Virologic suppression (HIV viral load <50 copies/mL) was achieved by the majority of patients in subcohorts 1 (88.9%) and 2 (85.7%) after initiation of DTG/3TC, with a median time to suppression of 11.2 (IQR, 6.2-30.0) and 20.6 (IQR, 10.5-32.4) weeks, respectively. Note that 1 patient in subcohort 2, who experienced virologic rebound, continued treatment with DTG/3TC.
These results may not be generalizable due to the small number of patients in the subcohorts.
“These real world results reflect data from clinical trials, demonstrating DTG/3TC is effective and well tolerated in the real world,” the researchers concluded.
Disclosure: Some authors have declared affiliations to the pharmaceutical industry. For a complete list of disclosures, please refer to the reference.
